Prognostic Value of IGF2 mRNA-Binding Protein 3 (IGF2BP3) Intratumoral Expression in Melanoma Patients at the Time of Diagnosis: Comparative Analysis of RT-qPCR Versus Immunohistochemistry.

MLA

Sánchez-Sendra, Beatriz, et al. “Prognostic Value of IGF2 MRNA-Binding Protein 3 (IGF2BP3) Intratumoral Expression in Melanoma Patients at the Time of Diagnosis: Comparative Analysis of RT-QPCR Versus Immunohistochemistry.” Cancers, vol. 14, no. 9, May 2022, p. N.PAG. EBSCOhost, https://doi.org/10.3390/cancers14092319.

APA

Sánchez-Sendra, B., Pérez-Debén, S., González-Muñoz, J. F., Murgui, A., & Monteagudo, C. (2022). Prognostic Value of IGF2 mRNA-Binding Protein 3 (IGF2BP3) Intratumoral Expression in Melanoma Patients at the Time of Diagnosis: Comparative Analysis of RT-qPCR Versus Immunohistochemistry. Cancers, 14(9), N.PAG. https://doi.org/10.3390/cancers14092319

Chicago

Sánchez-Sendra, Beatriz, Silvia Pérez-Debén, José F. González-Muñoz, Amelia Murgui, and Carlos Monteagudo. 2022. “Prognostic Value of IGF2 MRNA-Binding Protein 3 (IGF2BP3) Intratumoral Expression in Melanoma Patients at the Time of Diagnosis: Comparative Analysis of RT-QPCR Versus Immunohistochemistry.” Cancers 14 (9): N.PAG. doi:10.3390/cancers14092319.